Supernus Pharmaceuticals, Inc. (LON:0LB2)

Supernus Pharmaceuticals Statistics

Total Valuation

LON:0LB2 has a market cap or net worth of GBP 2.19 billion. The enterprise value is 2.02 billion.

Market Cap	2.19B
Enterprise Value	2.02B

Important Dates

The next estimated earnings date is Wednesday, February 25, 2026.

Earnings Date	Feb 25, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	57.34M
Shares Outstanding	n/a
Shares Change (YoY)	+0.54%
Shares Change (QoQ)	-0.16%
Owned by Insiders (%)	4.29%
Owned by Institutions (%)	101.89%
Float	54.86M

Valuation Ratios

PE Ratio	n/a
Forward PE	19.96
PS Ratio	4.32
PB Ratio	2.81
P/TBV Ratio	9.60
P/FCF Ratio	41.66
P/OCF Ratio	41.01
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 20.36, with an EV/FCF ratio of 38.29.

EV / Earnings	-141.72
EV / Sales	3.99
EV / EBITDA	20.36
EV / EBIT	81.02
EV / FCF	38.29

Financial Position

The company has a current ratio of 1.80, with a Debt / Equity ratio of 0.04.

Current Ratio	1.80
Quick Ratio	1.37
Debt / Equity	0.04
Debt / EBITDA	0.32
Debt / FCF	0.60
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -1.86% and return on invested capital (ROIC) is 1.96%.

Return on Equity (ROE)	-1.86%
Return on Assets (ROA)	1.52%
Return on Invested Capital (ROIC)	1.96%
Return on Capital Employed (ROCE)	3.08%
Revenue Per Employee	752,261
Profits Per Employee	-21,101
Employee Count	674
Asset Turnover	0.49
Inventory Turnover	1.06

Taxes

Income Tax	-1.20M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +45.83% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+45.83%
50-Day Moving Average	48.71
200-Day Moving Average	39.95
Relative Strength Index (RSI)	67.98
Average Volume (20 Days)	86

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	5.73

Income Statement

In the last 12 months, LON:0LB2 had revenue of GBP 507.02 million and -14.22 million in losses. Loss per share was -0.25.

Revenue	507.02M
Gross Profit	450.55M
Operating Income	24.96M
Pretax Income	-15.42M
Net Income	-14.22M
EBITDA	88.48M
EBIT	24.96M
Loss Per Share	-0.25

Balance Sheet

The company has 209.17 million in cash and 31.40 million in debt, giving a net cash position of 177.76 million.

Cash & Cash Equivalents	209.17M
Total Debt	31.40M
Net Cash	177.76M
Net Cash Per Share	n/a
Equity (Book Value)	780.89M
Book Value Per Share	13.67
Working Capital	195.85M

Cash Flow

In the last 12 months, operating cash flow was 53.47 million and capital expenditures -836,189, giving a free cash flow of 52.64 million.

Operating Cash Flow	53.47M
Capital Expenditures	-836,189
Free Cash Flow	52.64M
FCF Per Share	n/a

Margins

Gross margin is 88.86%, with operating and profit margins of 4.92% and -2.80%.

Gross Margin	88.86%
Operating Margin	4.92%
Pretax Margin	-3.04%
Profit Margin	-2.80%
EBITDA Margin	17.45%
EBIT Margin	4.92%
FCF Margin	10.38%

Dividends & Yields

LON:0LB2 does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.54%
Shareholder Yield	-0.54%
Earnings Yield	-0.65%
FCF Yield	2.40%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

LON:0LB2 has an Altman Z-Score of 4.52 and a Piotroski F-Score of 4.

Altman Z-Score	4.52
Piotroski F-Score	4